Rabab S Hamad
Overview
Explore the profile of Rabab S Hamad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hasan A, Cavalu S, Kira A, Hamad R, Abdel-Reheim M, Elmorsy E, et al.
Int J Nanomedicine
. 2025 Jan;
20():741-770.
PMID: 39845772
Different types of cancers affect the gastrointestinal tract (GIT), starting from the oral cavity and extending to the colon. In general, most of the current research focuses on the systemic...
2.
Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M, et al.
Int J Nanomedicine
. 2024 Dec;
19:13735-13762.
PMID: 39723173
Chronic wounds in diabetic patients experience significant clinical challenges due to compromised healing processes. Hypoxia-inducible factor-1 alpha (HIF-1α) is a critical regulator in the cellular response to hypoxia, enhancing angiogenesis...
3.
Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M, et al.
Front Pharmacol
. 2024 Nov;
15:1475998.
PMID: 39564119
Heat shock protein 90 (HSP90) is a pivotal molecular chaperone with multifaceted roles in cellular health and disease. Herein, we explore how HSP90 orchestrates cellular stress responses, particularly through its...
4.
Mohammed O, Youssef M, Hamad R, Abdel-Reheim M, Saleh L, Alamri M, et al.
PLoS One
. 2024 Oct;
19(10):e0312572.
PMID: 39480853
The development of new drugs for the inhibition of hepatocellular carcinoma (HCC) development and progression is a critical and urgent need. The median survival rate for HCC patients remains disappointingly...
5.
Aly I, Ibrahim E, Hamad R, Sayed H, Attiyah S, E-Komy W, et al.
Acta Parasitol
. 2024 Oct;
69(4):2097.
PMID: 39466538
No abstract available.
6.
Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies
Elmorsy E, Saber S, Hamad R, Abdel-Reheim M, El-Kott A, Alshehri M, et al.
Eur J Pharm Sci
. 2024 Oct;
203:106939.
PMID: 39423903
Cisplatin, a widely used chemotherapeutic agent, has proven efficacy against various malignancies. However, its clinical utility is hampered by its dose-limiting toxicities, including nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. This review...
7.
Abdelhamid A, Saber S, Hamad R, Abdel-Reheim M, Ellethy A, Amer M, et al.
Front Pharmacol
. 2024 Sep;
15:1454829.
PMID: 39309001
Introduction: Liver fibrosis is a significant global health burden that lacks effective therapies. It can progress to cirrhosis and hepatocellular carcinoma (HCC). Aberrant hedgehog pathway activation is a key driver...
8.
Cavalu S, Saber S, Ramadan A, Elmorsy E, Hamad R, Abdel-Reheim M, et al.
FASEB J
. 2024 Sep;
38(17):e70030.
PMID: 39221499
Citicoline, a compound produced naturally in small amounts in the human body, assumes a pivotal role in phosphatidylcholine synthesis, a dynamic constituent of membranes of neurons. Across diverse models of...
9.
Kira A, Elmorsy E, Hamad R, Abdel-Reheim M, Elhemely M, El Adle Khalaf N, et al.
Int Immunopharmacol
. 2024 Aug;
141:113000.
PMID: 39191124
Liver inflammatory diseases are marked by serious complications. Notably, nicardipine (NCD) has demonstrated anti-inflammatory properties, but its benefits in liver inflammation have not been studied yet. However, the therapeutic efficacy...
10.
Elmorsy E, Saber S, Hamad R, Abdel-Reheim M, Nadwa E, Alibrahim A, et al.
Life Sci
. 2024 Aug;
354:122966.
PMID: 39147320
Aberrant activation of the NLRP3 inflammasome is recognized to induce a chronic inflammatory response in the liver, ultimately leading to hepatic fibrosis. HSP90 is suggested to regulate NLRP3 activation and...